Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates.
about
Methods to Design and Synthesize Antibody-Drug Conjugates (ADCs)Antibody-drug conjugates as novel anti-cancer chemotherapeuticsSite-Dependent Degradation of a Non-Cleavable Auristatin-Based Linker-Payload in Rodent Plasma and Its Effect on ADC EfficacyAntibody drug conjugates: design and selection of linker, payload and conjugation chemistryCurrent Status: Site-Specific Antibody Drug ConjugatesOptimal Synthetic Glycosylation of a Therapeutic AntibodyOptimal Synthetic Glycosylation of a Therapeutic AntibodySpontaneous Isopeptide Bond Formation as a Powerful Tool for Engineering Site-Specific Antibody-Drug Conjugates.Complement factor P is a ligand for the natural killer cell-activating receptor NKp46.RF1 attenuation enables efficient non-natural amino acid incorporation for production of homogeneous antibody drug conjugates.Possible association between celiac disease and bacterial transglutaminase in food processing: a hypothesis.Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug developmentAn evolved Mxe GyrA intein for enhanced production of fusion proteinsNative mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate.Sugar-Protein Connectivity Impacts on the Immunogenicity of Site-Selective Salmonella O-Antigen Glycoconjugate Vaccines.Constitutive expression of active microbial transglutaminase in Escherichia coli and comparative characterization to a known variantField Guide to Challenges and Opportunities in Antibody-Drug Conjugates for Chemists.Emerging formats for next-generation antibody drug conjugates.Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates.Towards the next generation of biomedicines by site-selective conjugation.Emerging site-specific bioconjugation strategies for radioimmunotracer development.Locked by Design: A Conformationally Constrained Transglutaminase Tag Enables Efficient Site-Specific Conjugation.Insights from native mass spectrometry approaches for top- and middle- level characterization of site-specific antibody-drug conjugates.Microbial transglutaminase and c-myc-tag: a strong couple for the functionalization of antibody-like protein scaffolds from discovery platforms.Antibody-drug conjugates: recent advances in conjugation and linker chemistries.Structure of the Dispase Autolysis-inducing Protein from Streptomyces mobaraensis and Glutamine Cross-linking Sites for Transglutaminase.Discovery of a microbial transglutaminase enabling highly site-specific labeling of proteins.Chemoenzymatic strategy for the synthesis of site-specifically labeled immunoconjugates for multimodal PET and optical imaging.A Versatile Chemo-Enzymatic Conjugation Approach Yields Homogeneous and Highly Potent Antibody-Drug Conjugates.Bioorthogonal Click and Release Reaction of Iminosydnones with Cycloalkynes.Engineered, highly reactive substrates of microbial transglutaminase enable protein labeling within various secondary structure elements.Nanobodies: Chemical Functionalization Strategies and Intracellular Applications.Dual, Site-Specific Modification of Antibodies by Using Solid-Phase Immobilized Microbial Transglutaminase.Site-Selective Labeling of Native Proteins by a Multicomponent Approach.Enzymatic conjugation using branched linkers for constructing homogeneous antibody-drug conjugates with high potency.Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27-28, 2017, Tours, France.Illuminating structure and acyl donor sites of a physiological transglutaminase substrate from Streptomyces mobaraensis.An efficient protocol towards site-specifically clickable nanobodies in high yield: cytoplasmic expression in Escherichia coli combined with intein-mediated protein ligation.Site-Specific Antibody Conjugation for ADC and Beyond.Glutamic acid-valine-citrulline linkers ensure stability and efficacy of antibody-drug conjugates in mice.
P2860
Q26768654-EA89846C-DE1B-438D-9136-C57D7DE9A768Q26800175-8DE6A458-4D57-4FAE-93C3-C75DBA15BA9EQ27303016-052815F9-FE43-4606-8C89-743B13B5ACA1Q28544658-0BAF1A21-D48D-413F-9D85-887B4F06C66FQ28829290-49C3509C-D751-450E-80E8-A0518A444843Q28831266-90FFF87C-D969-4B7A-9283-BF0AE68953ECQ28831364-13D6B4EC-5CDE-42BC-BD14-71BEC20E5260Q30396530-59E77EBB-4629-440D-A77B-13EBAC6B06E7Q33642649-F40C9BCF-CF8E-47A9-9B5E-BEC2817E802AQ33780009-3E46F825-D77D-44E1-8CA6-C065EECE6D74Q34481156-59C21E83-A7BD-491C-BB49-A3E33DCB56C4Q35105725-4A2FDD34-E61B-4B29-92BD-A535E24F57F4Q35121107-1038AD27-3B69-4838-B2F6-D79C605821A9Q35946005-24FC5062-7C3A-476F-997A-282D06BCE698Q36287530-F300DACD-5A1E-4612-BF15-8491E52D644AQ36293181-D6B277C0-3B27-4EFA-AEC3-639617282B03Q37066113-4F73497A-FE0E-4EF6-89EA-4D06792D0264Q38386705-58C50805-7355-45FF-836B-6EAED1C3BCDDQ38665164-5B4322DF-C2B1-4DD8-ADBA-C4B10BF5BF84Q38706553-BF3EE4DF-7220-4E20-B589-4CFF7D143E6AQ38818208-382E4DFA-2915-4A3A-A67F-64A2CEEF78D8Q38835486-AF315909-1C65-4D2C-B0C6-BC92D4EDF389Q38838739-99252BC3-F119-438F-9EBD-8046BE5AD8BDQ38908797-C0E45501-B09A-41F5-AD1D-F2FD912CEEE1Q38981429-0A8FABAB-ADFF-4CB3-A4B4-9C69E6CFFAEEQ39522120-3F6FCFB5-ECA6-4EEE-8E3F-01478AF2188BQ41685401-79273C7B-70FE-4913-88FA-4E7F8CB778C4Q42556439-BA14F47A-28D6-41F0-84EF-00F9A1BECF22Q47095655-37A30BF9-47B7-49D3-8401-FC32F4F0FE89Q47634347-917A660A-DE74-4F93-B946-4A2613AE1F50Q47735594-415505EC-829C-4237-B6B1-E68DFB425EA9Q47797367-A8B95494-3F63-4678-8FA1-C0EF62FCC857Q47994940-11DC8B72-A552-4178-BB02-5C31E8C4E016Q48263109-DD337AD4-C31F-4601-968C-090D4C2688F7Q48742034-8778F5CF-F6F3-489C-BE19-124A1D572A8FQ49846411-2B862639-C776-4B9A-A391-664D4F36FCD0Q50071272-8815112D-BCCA-408C-BEEF-333777DC27D0Q51820924-223D4835-A8FF-4579-AA91-5BB4C07D0B98Q55022669-AE6E345F-E8BA-4627-A456-A7FD10EC87DAQ55385806-F4AB2376-767D-40FD-B5BC-88BDFD92BF5F
P2860
Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Transglutaminase-based chemo-e ...... eous antibody-drug conjugates.
@en
Transglutaminase-based chemo-e ...... eous antibody-drug conjugates.
@nl
type
label
Transglutaminase-based chemo-e ...... eous antibody-drug conjugates.
@en
Transglutaminase-based chemo-e ...... eous antibody-drug conjugates.
@nl
prefLabel
Transglutaminase-based chemo-e ...... eous antibody-drug conjugates.
@en
Transglutaminase-based chemo-e ...... eous antibody-drug conjugates.
@nl
P2093
P50
P356
P1476
Transglutaminase-based chemo-e ...... neous antibody-drug conjugates
@en
P2093
Christian Belmant
Delphine Brégeon
Florence Lhospice
François Romagne
Laurent Gauthier
Patrick Dennler
P304
P356
10.1021/BC400574Z
P577
2014-02-12T00:00:00Z